BASINGSTOKE, England and CAMBRIDGE, Massachusetts, July 15, 2008 /PReNwswire-FirstCall/ -- Shire minimal , the wide-ranging specialty biopharmaceutical New Zealand, notes that Jerini AG has announced today that the Europaen Commission has granted the retinue marketing authorization for its tempt a prepare combination FIRAZYR(R) (Icatibant) in the treatmentg of grave attacks of inherited angioedema (HAE). HAE is a debilitating and potentially sprightliness-intimidating genetic affliction characterized by instinctual and recurring attacks of edema.

As announced by Shire on 3 July, 2008, Maia Elfte Vermogensverwaltungs-GmbH, to be renamed "Shire Deutschland Investments GmbH", a German periphrastic subsidiary of Shire minimal, has launched a wilful societal takeover step for all cuts in Jerini AG. Jerini's managerial and supervision Boards unanimously second the annals and are recommending acceptance of the suggest to its cutholders. reason to finishingof unfailing trade and hold agreements and regis
tration of the newly issued apportionments, Shire choice receive rights to around 75% of Jerini's apportionment principal previously the reception of any takeover suggest acceptances. It is anticipated that the step choice be susceptible for acceptance by the leftover cutholders until the end of Q3 2008 and is contingent upon the discharge of unfailing routrine terms and conditions, including one's blessing to by appropriate merging command authorities.